Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LIFECORE BIOMEDICAL, INC. \DE\LFCR · Entity 6447 | Chief Legal & Administration | April 14, 2026 | April 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LIFECORE BIOMEDICAL, INC. \DE\
Report date April 14, 2026 · Filed April 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 246,333 |
Reported balance
After 2026-04-14 transaction · row 1
1 source rowRow 1 · 2026-04-14 · Tax withholding · Disposed 24,645 · Balance 246,333 F1: Represents number of shares withheld by the issuer to satisfy applicable tax withholding obligations in connection with the vesting and settlement of an RSU vesting. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents number of shares withheld by the issuer to satisfy applicable tax withholding obligations in connection with the vesting and settlement of an RSU vesting.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 14, 2026 Filed Apr 16, 2026 20:39 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LFCR · Entity 6447 | Tax withholdingCommon Stock | 24,645 | $5.20 | $128,154.00 |
DisclosureSEC source: 0002062209-26-000004 · wk-form4_1776371972.xml · nonDerivative · entry 1 Salus Thomas D. · CIK 0002062209 · Chief Legal & Administration 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 246,333 F1 · shares: Represents number of shares withheld by the issuer to satisfy applicable tax withholding obligations in connection with the vesting and settlement of an RSU vesting. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 23:52 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LFCR · Entity 6447 | GrantCommon Stock | 30,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0002062209-26-000002 · wk-form4_1772495559.xml · nonDerivative · entry 1 Salus Thomas D. · CIK 0002062209 · Chief Legal & Administration 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 270,978 F1 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. F2 · price: Restricted Stock Units will vest on the 3rd anniversary of the grant date. Read SEC document |
| July 08, 2025 Filed Jul 10, 2025 20:45 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LFCR · Entity 6447 | Exercise / conversionPerformance-Based Restricted Stock Units · Derivative | 37,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001005286-25-000080 · wk-form4_1752180336.xml · derivative · entry 3 Salus Thomas D. · CIK 0002062209 · Chief Legal & Administration 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 333,000 Underlying: Common Stock · 37,000 shares Expires 2030-04-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's common stock upon the Issuer's common stock achieving certain stock prices. F2 · price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's common stock upon the Issuer's common stock achieving certain stock prices. F2 · derivative.exercise_date: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's common stock upon the Issuer's common stock achieving certain stock prices. Read SEC document |
| July 08, 2025 Filed Jul 10, 2025 20:45 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LFCR · Entity 6447 | Tax withholdingCommon Stock | 11,022 | $8.19 | $90,270.18 |
DisclosureSEC source: 0001005286-25-000080 · wk-form4_1752180336.xml · nonDerivative · entry 2 Salus Thomas D. · CIK 0002062209 · Chief Legal & Administration 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 240,978 F3 · shares: Represents number of shares withheld by the issuer to satisfy applicable tax withholding obligations in connection with the vesting and settlement of the performance stock unit award as reported in Table I. Read SEC document |
| July 08, 2025 Filed Jul 10, 2025 20:45 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LFCR · Entity 6447 | Exercise / conversionCommon Stock | 37,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001005286-25-000080 · wk-form4_1752180336.xml · nonDerivative · entry 1 Salus Thomas D. · CIK 0002062209 · Chief Legal & Administration 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 252,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The performance-based restricted stock units vested based on the Issuer's achievement of a stock price milestone. F2 · price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's common stock upon the Issuer's common stock achieving certain stock prices. Read SEC document |
| April 14, 2025 Filed Apr 16, 2025 20:38 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LFCR · Entity 6447 | GrantIncentive Stock Option (Right to Buy) · Derivative | 210,000 | $0.00 Strike: $6.17 | $0.00 |
DisclosureSEC source: 0001005286-25-000070 · wk-form4_1744835921.xml · derivative · entry 4 Salus Thomas D. · CIK 0002062209 · Chief Legal & Administration 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 210,000 Underlying: Common Stock · 210,000 shares Expires 2032-04-14 Read SEC document |
| April 14, 2025 Filed Apr 16, 2025 20:38 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LFCR · Entity 6447 | GrantPerformance-Based Restricted Stock Units · Derivative | 370,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001005286-25-000070 · wk-form4_1744835921.xml · derivative · entry 3 Salus Thomas D. · CIK 0002062209 · Chief Legal & Administration 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 370,000 shares Expires 2030-04-14 F2 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · shares: Represents the maximum number of performance-based restricted stock units that can vest based on the Issuer's achievement of certain stock price milestones. F4 · derivative.exercise_date: The performance-based restricted stock units vest, if at all, based on the Issuer's achievement of certain stock prices. F3 · derivative.underlying_shares: Represents the maximum number of performance-based restricted stock units that can vest based on the Issuer's achievement of certain stock price milestones. Read SEC document |
| April 14, 2025 Filed Apr 16, 2025 20:38 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LFCR · Entity 6447 | GrantCommon Stock | 170,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001005286-25-000070 · wk-form4_1744835921.xml · nonDerivative · entry 2 Salus Thomas D. · CIK 0002062209 · Chief Legal & Administration 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 215,000 F1 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. Read SEC document |
| April 14, 2025 Filed Apr 16, 2025 20:38 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LFCR · Entity 6447 | GrantCommon Stock | 45,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001005286-25-000070 · wk-form4_1744835921.xml · nonDerivative · entry 1 Salus Thomas D. · CIK 0002062209 · Chief Legal & Administration 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 F1 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.